June 13, 2025

Clonal hematopoiesis landscape in frequent blood donors

Clonal hematopoiesis landscape in frequent blood donors

Key Points

  • CH analysis of a unique and uniform cohort of exclusively healthy individuals exposed to a novel type of selection pressure was conducted.
  • Novel EPO-responsive DNMT3A mutations with distinct in vivo and in vitro growth behavior were identified.

Abstract

Donor blood saves lives, yet the potential impact of recurrent large-volume phlebotomy on donor health and hematopoietic stem cells (HSCs) remains largely unexplored. In our study, we conducted a comprehensive screening of 217 older male volunteer donors with a history of extensive blood donation (>100 lifetime donations) to investigate the phenomenon of clonal hematopoiesis (CH). No significant difference in the overall incidence of CH was found in frequent donors (FDs) compared with sporadic donors (<10 lifetime donations; 212 donors). However, upon deeper analysis of mutations in DNMT3A, the most commonly affected gene in CH, we observed distinct mutational patterns between the FD and age/sex-matched control donor cohorts. Functional analysis of FD-enriched DNMT3A variants examined in CRISPR-edited human HSCs demonstrated their competitive outgrowth potential upon stimulation with erythropoietin (EPO), a hormone that increases in response to blood loss. In contrast, clones harboring leukemogenic DNMT3A R882 mutations increase upon stimulation with interferon gamma. Through concurrent mutational and immunophenotypic profiling of primary samples at single-cell resolution, a myeloid bias of premalignant R882 mutant HSCs was found, whereas no significant lineage bias was observed in HSCs harboring EPO-responsive DNMT3A variants. The latter exhibited preferential erythroid differentiation when persistent erythropoietic stress was applied to CRISPR-edited human HSC xenografts. Our data demonstrate a nuanced, ongoing Darwinian evolution at the somatic stem cell level, with EPO identified as a novel environmental factor that favors HSCs carrying certain DNMT3A mutations.

Karpova D, Huerga Encabo H, Donato E, Calderazzo S, Scherer M, Llorian-Sopena M, Leppä AM, Würth R, Stelmach P, Papazoglou D, Ferrelli A, Ngo S, Kotova I, Harenkamp S, Zimmer K, Wolf D, Panten J, Reed J, Przybylla A, Tonn T, Kopp-Schneider A, Velten L, DiPersio JF, Wong TN, Bonnet D, Bonig H, Trumpp A.

Subjects: 
Hematopoiesis and Stem CellsPlenary PapersTransfusion Medicine

Our latest News

discover more
RHEACELL makes second location in Heidelberg visible

RHEACELL makes second location in Heidelberg visible

Heidelberg, January 28, 2026 – RHEACELL GmbH & Co. KG is continuing to expand its presence in Heidelberg and moved into a second location in the Pfaffengrund district in August last year. At the start of the year, the location is now also becoming visible to the outside world: this week, the company logo will […]

TUM Researchers receive two ERC Grants

TUM Researchers receive two ERC Grants

The European Research Council’s (ERC) Proof of Concept Grants are designed to help researchers turn their findings into real‑world innovations. Two ERC‑funded follow‑up projects at TUM will each receive approximately 150,000 euros in support. The projects focus on virus‑driven cancer treatments and new ways to supply electrons for enzyme‑based technologies. Researchers at TUM have secured […]

Weight Loss in Cancer: Organs Respond to the Disease in a Coordinated Way

Weight Loss in Cancer: Organs Respond to the Disease in a Coordinated Way

Cachexia is a metabolic disorder that causes uncontrolled weight loss and muscle wasting in chronic diseases and cancer. A new study by Helmholtz Munich, in collaboration with the Institute of Physiology of the Czech Academy of Sciences in Prague, Heidelberg University Hospital, the German Center for Diabetes Research (DZD), and the German Center for Cardiovascular […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp